Brief: Ventyx Biosciences Announces Results From The Phase 2 Trial Of VTX958 In Patients With Moderate To Severe Plaque Psoriasis

Ventyx Biosciences

06/11/2023 21:03

Nov 6 (Reuters) - Ventyx Biosciences Inc  VTYX.O :
    * VENTYX BIOSCIENCES ANNOUNCES RESULTS FROM THE PHASE 2
TRIAL OF
VTX958 IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS AND
PROVIDES CORPORATE UPDATE
    * VENTYX BIOSCIENCES INC - CASH, CASH EQUIVALENTS AND
MARKETABLE
SECURITIES OF $300.8M AS OF SEPTEMBER 30, 2023
    * VENTYX BIOSCIENCES INC - ONGOING PHASE 2 TRIAL OF VTX958
IN
CROHN'S DISEASE WILL CONTINUE TO ENROLL
    * VENTYX BIOSCIENCES INC: ONGOING PHASE 2 TRIAL OF VTX958 IN
CROHN'S DISEASE WILL CONTINUE TO ENROLL; VENTYX INTENDS TO
CONDUCT AN INTERIM EFFICACY ANALYSIS IN Q1 2024
    * VENTYX BIOSCIENCES INC - EFFICACY RESULTS DID NOT MEET
INTERNAL
TARGET TO SUPPORT FURTHER DEVELOPMENT OF VTX958 IN PSORIASIS
    * VENTYX BIOSCIENCES INC - VENTYX INTENDS TO CONDUCT AN
INTERIM
EFFICACY ANALYSIS IN Q1 2024
    * VENTYX BIOSCIENCES INC - VENTYX TO TERMINATE PHASE 2
TRIALS OF
VTX958 IN PLAQUE PSORIASIS AND PSORIATIC ARTHRITIS
    * VENTYX BIOSCIENCES INC - PHASE 2 TRIAL OF VTX958 IN
CROHN'S
DISEASE TO CONTINUE TO ENROLL; INTENDS TO CONDUCT INTERIM
EFFICACY ANALYSIS IN Q1 2024

Source text for Eikon:  ID:nGNX5DbV4W 
Further company coverage:  VTYX.O 

 ((Reuters.Briefs@thomsonreuters.com))